Над 1000 научни изследвания доказват, че експерименталните инжекционни течности срещу «СОVID-19» са изключително опасни (СПИСЪК)

В рамките на 12-те месеца, откакто се настоява обществеността да приема експерименталните ваксини за СОVID-19, са проведени над 1000 научни изследвания, които неопровержимо доказват, че ваксините за СОVID-19 са изключително опасни.

Освен безбройния брой смъртни случаи, причинени от тези ваксини, те причиняват и сериозни увреждания и медицински състояния, включително съсирване на кръвта, миокардит, перикардит, тромбоза, тромбоцитопения, анафилаксия, парализа на Бел, Гилен-Баре и рак.

Списъкът по-долу съдържа над 1000 научни изследвания и статии от реномирани медицински списания и е съставен от британската организация Save Us Now.

Направихме копие на техния списък тук, в случай че уебсайтът им е хакнат или свален по някаква причина, но също така почистихме списъка им, тъй като имаше някои дублиращи се записи и счупени връзки.

Можете да видите оригиналната връзка и да подкрепите работата им на адрес:
https://www.saveusnow.org.uk/covid-vaccine-scientific-proof-lethal/.“
Източник: Health Glade
Превод на български – Страничката „Монтагю Кийн“

БЕЛЕЖКА НА РЕДАКТОРА

Научните институции и лаборатории от целия свят, които потвърждават, че СОVID-19 наистина НЕ съществува вече са 177 👇
(СТО СЕДЕМДЕСЕТ И СЕДЕМ)
.
Наградата от 1 млн. долара за този, който докаже, че СОVID-19 наистина съществува също чака доказателства, ама знаете ли кога ще ги получат? 👇
(НИКОГА).
Депопулацията чрез ПРИНУДИТЕЛНА ВАКСИНАЦИЯ бе обявена от главния антихрист на планетата още през 2011 година! 👇
(ВИДЕА)

ОЩЕ МНОГО ПО ТЕМАТА ТУК!

Който желае може да се присъедини към групата «Неваксинираната сперма е следващият биткойн»

СПИСЪК

  1. Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/
  2. Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination: https://www.sciencedirect.com/science/article/pii/S1052305721003414
  3. Fatal cerebral hemorrhage after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928772/
  4. Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: https://www.sciencedirect.com/science/article/pii/S2666602221000409
  5. Three cases of acute venous thromboembolism in women after vaccination against COVID-19: https://www.sciencedirect.com/science/article/pii/S2213333X21003929
  6. Acute thrombosis of the coronary tree after vaccination against COVID-19: https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988
  7. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020:
    https://pubmed.ncbi.nlm.nih.gov/33929487/
  8. Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/
  9. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
  10. Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review:
    https://www.sciencedirect.com/science/article/pii/S0022510X21003014
  11. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381
  12. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505
  13. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904
  14. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: https://www.sciencedirect.com/science/article/pii/S1665268121000557
  15. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): https://www.sciencedirect.com/science/article/pii/S1050173821000967
  16. Roots of autoimmunity of thrombotic events after COVID-19 vaccination: https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160
  17. Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext
  18. Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine:
    https://www.nejm.org/doi/full/10.1056/nejme2106315
  19. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
  20. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19:
    https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article
  21. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
  22. Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19:
    https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article
  23. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): https://haematologica.org/article/view/haematol.2021.279075
  24. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS):
    https://www.sciencedirect.com/science/article/pii/S0264410X21005247
  25. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination: https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478
  26. Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man:
    https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005
  27. Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines:
    https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895
  28. Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination:
    https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315
  29. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: https://www.sciencedirect.com/science/article/pii/S0896841121000937
  30. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098
  31. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT):
    https://www.sciencedirect.com/science/article/pii/S0953620521002363
  32. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: https://www.sciencedirect.com/science/article/pii/S0828282X21006243
  33. “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: https://www.sciencedirect.com/science/article/pii/S2666572721000389
  34. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S:
    https://www.sciencedirect.com/science/article/pii/S0196064421003425
  35. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S1443950621011562
  36. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706
  37. Prothrombotic immune thrombocytopenia after COVID-19 vaccination:
    https://www.sciencedirect.com/science/article/pii/S0006497121009411
  38. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: https://www.sciencedirect.com/science/article/pii/S2589936821000256
  39. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046
  40. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https://www.sciencedirect.com/science/article/pii/S0049384821004369
  41. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19:
    https://www.sciencedirect.com/science/article/pii/S0735109721051949
  42. A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination:
    https://www.sciencedirect.com/science/article/pii/S0735675721005714
  43. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom:
    https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X
  44. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963
  45. Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: https://pubmed.ncbi.nlm.nih.gov/34090785/
  46. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?:
    https://www.sciencedirect.com/science/article/pii/S0953620521002314
  47. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination:
    https://www.sciencedirect.com/science/article/pii/S0213485321000839
  48. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: https://pubmed.ncbi.nlm.nih.gov/33918932/
  49. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33606296/
  50. Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33854395/
  51. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine:
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/
  52. COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: https://pubmed.ncbi.nlm.nih.gov/33863748/
  53. Cerebral venous thrombosis associated with the covid-19 vaccine in Germany:
    https://onlinelibrary.wiley.com/doi/10.1002/ana.26172
  54. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: https://pubmed.ncbi.nlm.nih.gov/34133027/
  55. The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34001390/
  56. Thrombosis with thrombocytopenia after messenger RNA vaccine -1273:
    https://pubmed.ncbi.nlm.nih.gov/34181446/
  57. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
  58. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland:
    https://www.nature.com/articles/s41591-021-01408-4
  59. Exacerbation of immune thrombocytopenia after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34075578/
  60. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105244/
  61. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia:
    https://www.nejm.org/doi/full/10.1056/NEJMc2106383
  62. Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia:
    https://www.nature.com/articles/s41586-021-03744-4
  63. Myocarditis with COVID-19 mRNA vaccines:
    https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135
  64. Myocarditis and pericarditis after COVID-19 vaccination:
    https://jamanetwork.com/journals/jama/fullarticle/2782900
  65. Myocarditis temporally associated with COVID-19 vaccination:
    https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891
  66. COVID-19 Vaccination Associated with Myocarditis in Adolescents:
    https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf
  67. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/33994339/
  68. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature:
    https://www.sciencedirect.com/science/article/pii/S1553838921005789
  69. COVID-19 vaccine-induced myocarditis: a case report with review of the literature:
    https://www.sciencedirect.com/science/article/pii/S1871402121002253
  70. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings:
    https://www.sciencedirect.com/science/article/pii/S1936878X2100485X
  71. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent:
    https://www.sciencedirect.com/science/article/pii/S002234762100617X
  72. Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients:
    https://www.sciencedirect.com/science/article/pii/S0167527321012286
  73. Acute myocarditis after administration of BNT162b2 vaccine:
    https://www.sciencedirect.com/science/article/pii/S2214250921001530
  74. Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: https://www.sciencedirect.com/science/article/pii/S2352906721001573
  75. Myocarditis following vaccination with BNT162b2 in a healthy male:
    https://www.sciencedirect.com/science/article/pii/S0735675721005362
  76. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection:
    https://www.sciencedirect.com/science/article/pii/S1930043321005549
  77. Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents:
    https://www.sciencedirect.com/science/article/pii/S002234762100665X
  78. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine:
    https://www.sciencedirect.com/science/article/pii/S1885585721002218
  79. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA:
    https://www.sciencedirect.com/science/article/pii/S2589790X21001931
  80. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection:
    https://www.sciencedirect.com/science/article/pii/S2352906721000622
  81. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: https://www.sciencedirect.com/science/article/pii/S0022347621007368
  82. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man:
    https://www.sciencedirect.com/science/article/pii/S0870255121003243
  83. Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: https://www.sciencedirect.com/science/article/pii/S0022347621007496
  84. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2:
    https://www.sciencedirect.com/science/article/pii/S1936878X21004861
  85. Takotsubo cardiomyopathy after vaccination with mRNA COVID-19:
    https://www.sciencedirect.com/science/article/pii/S1443950621011331
  86. COVID-19 mRNA vaccination and myocarditis:
    https://pubmed.ncbi.nlm.nih.gov/34268277/
  87. COVID-19 vaccine and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34399967/
  88. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study:
    https://doi.org/10.3346/jkms.2021.36.e232
  89. COVID-19 vaccines and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34246566/
  90. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp lications-of-the-mrna-based-covid-19-vaccines:
    https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines
  91. Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34340927/
  92. Myocarditis with covid-19 mRNA vaccines:
    https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135
  93. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
  94. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C
  95. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600
  96. Myocarditis following immunization with Covid-19 mRNA:
    https://www.nejm.org/doi/full/10.1056/NEJMc2109975
  97. Patients with acute myocarditis after vaccination withCOVID-19 mRNA:
    https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602
  98. Myocarditis associated with vaccination with COVID-19 mRNA:
    https://pubs.rsna.org/doi/10.1148/radiol.2021211430
  99. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: https://pediatrics.aappublications.org/content/148/3/e2021052478
  100. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4
  101. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis
  102. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA:
    https://pubmed.ncbi.nlm.nih.gov/34402228/
  103. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
  104. Myocarditis / pericarditis associated with COVID-19 vaccine:
    https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html
  105. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx
  106. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine:
    https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543
  107. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/
  108. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database:
    https://pubmed.ncbi.nlm.nih.gov/34219532/
  109. Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination:
    https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033
  110. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings:
    https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236
  111. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine:
    https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038
  112. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?:
    https://pubmed.ncbi.nlm.nih.gov/34333695/
  113. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent:
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/
  114. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?:
    https://pubmed.ncbi.nlm.nih.gov/34118375/
  115. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34180390/
  116. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
  117. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
  118. Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis:
    https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059
  119. Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: https://pubmed.ncbi.nlm.nih.gov/34447639/
  120. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Moderna) mRNA-1273 vaccine in a young healthy male: case report:
    https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183-3
  121. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: https://pubmed.ncbi.nlm.nih.gov/34236331/
  122. Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34435250/
  123. COVID-19 vaccine-induced rhabdomyolysis: case report with literature review:
    https://pubmed.ncbi.nlm.nih.gov/34186348/
  124. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development:
    https://www.sciencedirect.com/science/article/pii/S2666354621000065
  125. Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: https://www.sciencedirect.com/science/article/pii/S0303846721004169
  126. Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature:
    https://www.sciencedirect.com/science/article/pii/S0165572821002186
  127. Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association:
    https://www.sciencedirect.com/science/article/pii/S2214250921000998
  128. Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: https://www.sciencedirect.com/science/article/pii/S0736467921006442
  129. Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://www.sciencedirect.com/science/article/pii/S0035378721005853.
  130. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: https://www.sciencedirect.com/science/article/pii/S2049080121005343
  131. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report:
    https://www.sciencedirect.com/science/article/pii/S2049080121007536
  132. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database:
    https://www.sciencedirect.com/science/article/pii/S1201971221007049
  133. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence:
    https://www.sciencedirect.com/science/article/pii/S0899707121003557.
  134. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination:
    https://www.sciencedirect.com/science/article/pii/S0165572821001569
  135. Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association:
    https://www.sciencedirect.com/science/article/pii/S0165572821002137
  136. Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story:
    https://www.sciencedirect.com/science/article/pii/S1473309921002735
  137. Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy:
    https://www.sciencedirect.com/science/article/pii/S266635462100020X
  138. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine: https://www.sciencedirect.com/science/article/pii/S2451993621001456
  139. Bell’s palsy after COVID-19 vaccination: case report:
    https://www.sciencedirect.com/science/article/pii/S217358082100122X
  140. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history:
    https://www.sciencedirect.com/science/article/pii/S2213219821007972
  141. COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET:
    https://www.sciencedirect.com/science/article/pii/S1930043321002612
  142. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine:
    https://www.sciencedirect.com/science/article/pii/S0272638621007423
  143. Late cutaneous reactions after administration of COVID-19 mRNA vaccines:
    https://www.sciencedirect.com/science/article/pii/S2213219821007996
  144. COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature:
    https://www.sciencedirect.com/science/article/pii/S1871402121001880
  145. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study:
    https://www.sciencedirect.com/science/article/pii/S0190962221024427
  146. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:.
    https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381
  147. COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:.
    https://www.sciencedirect.com/science/article/pii/S1939455121000119
  148. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046
  149. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:
    https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X
  150. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:
    https://www.sciencedirect.com/science/article/pii/S0896841121000937
  151. immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine: https://www.sciencedirect.com/science/article/pii/S2214250921002018
  152. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report:
    https://www.sciencedirect.com/science/article/pii/S1876034121001878
  153. COVID-19 RNA-based vaccines and the risk of prion disease: https://scivisionpub.com/pdfs/covid19-rna-based-vaccines-and-the-risk-of-prion-disease-1503.pdf.pdf
  154. This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines:
    https://www.nejm.org/doi/full/10.1056/NEJMoa2104983
  155. Process-related impurities in the ChAdOx1 nCov-19 vaccine:
    https://www.researchsquare.com/article/rs-477964/v1
  156. COVID-19 mRNA vaccine causing CNS inflammation: a case series:
    https://link.springer.com/article/10.1007/s00415-021-10780-7
  157. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33475702/
  158. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol:
    https://pubmed.ncbi.nlm.nih.gov/33320974/
  159. Pfizer Vaccine Raises Allergy Concerns: https://pubmed.ncbi.nlm.nih.gov/33384356/
  160. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020:
    https://pubmed.ncbi.nlm.nih.gov/33444297/
  161. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021:
    https://pubmed.ncbi.nlm.nih.gov/33507892/
  162. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: https://pubmed.ncbi.nlm.nih.gov/34414880/
  163. Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: https://pubmed.ncbi.nlm.nih.gov/33576785/
  164. Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: https://pubmed.ncbi.nlm.nih.gov/34269740/
  165. Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34215453/
  166. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research:
    https://pubmed.ncbi.nlm.nih.gov/33932618/
  167. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): https://pubmed.ncbi.nlm.nih.gov/33643776/
  168. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines:
    https://pubmed.ncbi.nlm.nih.gov/33571463/
  169. Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: https://pubmed.ncbi.nlm.nih.gov/33527524/
  170. Cutaneous adverse effects of available COVID-19 vaccines:
    https://pubmed.ncbi.nlm.nih.gov/34518015/
  171. Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report:
    https://pubmed.ncbi.nlm.nih.gov/34347278/
  172. COVID-19 vaccines increase the risk of anaphylaxis:
    https://pubmed.ncbi.nlm.nih.gov/33685103/
  173. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
  174. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation:
    https://pubmed.ncbi.nlm.nih.gov/33657648/
  175. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33825239/
  176. Acute allergic reactions to COVID-19 mRNA vaccines:
    https://pubmed.ncbi.nlm.nih.gov/33683290/
  177. Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2:
    https://pubmed.ncbi.nlm.nih.gov/33919151/
  178. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: https://pubmed.ncbi.nlm.nih.gov/34128049/
  179. Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: https://pubmed.ncbi.nlm.nih.gov/34474708/
  180. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI):
    https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447
  181. .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34318537/
  182. Allergic reactions after COVID-19 vaccination: putting the risk in perspective:
    https://pubmed.ncbi.nlm.nih.gov/34463751/
  183. Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: https://pubmed.ncbi.nlm.nih.gov/33846043/ 188/.
  184. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: https://pubmed.ncbi.nlm.nih.gov/33752263/
  185. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
  186. Fatal brain hemorrhage after COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/33928772/
  187. A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: https://pubmed.ncbi.nlm.nih.gov/34423106/
  188. Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/
  189. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: https://pubmed.ncbi.nlm.nih.gov/34517079/
  190. Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: https://pubmed.ncbi.nlm.nih.gov/34254291/
  191. Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry:
    https://pubmed.ncbi.nlm.nih.gov/34487581/
  192. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome:
    https://pubmed.ncbi.nlm.nih.gov/33987882/
  193. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34138513/
  194. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea:
    https://pubmed.ncbi.nlm.nih.gov/34402235/
  195. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study:
    https://pubmed.ncbi.nlm.nih.gov/34446426/
  196. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review:
    https://pubmed.ncbi.nlm.nih.gov/34365148/
  197. Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: https://pubmed.ncbi.nlm.nih.gov/34452064/
  198. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/33917902/
  199. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT):
    https://pubmed.ncbi.nlm.nih.gov/34256983/
  200. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/
  201. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34132839/
  202. 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34117206/
  203. Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience:
    https://pubmed.ncbi.nlm.nih.gov/34033927/
  204. Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
  205. Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34364831/
  206. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: https://pubmed.ncbi.nlm.nih.gov/34447639/
  207. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34514306/
  208. Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2:
    https://pubmed.ncbi.nlm.nih.gov/33946748/
  209. Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis:
    https://pubmed.ncbi.nlm.nih.gov/34453510/
  210. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/33476455/
  211. Propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34451967/
  212. Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34377889/
  213. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
  214. COVID-19 vaccination association and facial nerve palsy: A case-control study:
    https://pubmed.ncbi.nlm.nih.gov/34165512/
  215. The association between COVID-19 vaccination and Bell’s palsy:
    https://pubmed.ncbi.nlm.nih.gov/34411533/
  216. Bell’s palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33611630/
  217. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): https://pubmed.ncbi.nlm.nih.gov/33981305/
  218. Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34336436/
  219. Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34281950/
  220. Transverse myelitis induced by SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34458035/
  221. Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19):
    https://pubmed.ncbi.nlm.nih.gov/33734623/
  222. Acute abducens nerve palsy after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34044114/
  223. Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: https://pubmed.ncbi.nlm.nih.gov/34492394/
  224. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34369471/
  225. Bell’s palsy after Ad26.COV2.S COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34014316/
  226. Bell’s palsy after COVID-19 vaccination: case report:
    https://pubmed.ncbi.nlm.nih.gov/34330676/
  227. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34272622/
  228. Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34477091/
  229. Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33975372/
  230. Bell’s palsy after COVID-19 vaccination with high antibody response in CSF:
    https://pubmed.ncbi.nlm.nih.gov/34322761/.
  231. Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519:
    https://pubmed.ncbi.nlm.nih.gov/34139321/
  232. Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report:
    https://pubmed.ncbi.nlm.nih.gov/34032902/
  233. Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: https://pubmed.ncbi.nlm.nih.gov/33862041/
  234. Autoimmune hepatitis triggered by vaccination against SARS-CoV-2:
    https://pubmed.ncbi.nlm.nih.gov/34332438/
  235. Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity:
    https://pubmed.ncbi.nlm.nih.gov/34293683/
  236. Autoimmune hepatitis after COVID vaccine: https://pubmed.ncbi.nlm.nih.gov/34225251/
  237. A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: https://pubmed.ncbi.nlm.nih.gov/34449715/
  238. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://pubmed.ncbi.nlm.nih.gov/34139631/
  239. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19:
    https://pubmed.ncbi.nlm.nih.gov/33864750/
  240. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/33914590/
  241. Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19:
    https://pubmed.ncbi.nlm.nih.gov/34420802/
  242. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency:
    https://pubmed.ncbi.nlm.nih.gov/34293217/
  243. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study:
    https://pubmed.ncbi.nlm.nih.gov/34446426/
  244. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
  245. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
  246. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland:
    https://pubmed.ncbi.nlm.nih.gov/34108714/
  247. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany:
    https://pubmed.ncbi.nlm.nih.gov/34288044/
  248. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34341358/
  249. Celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence:
    https://pubmed.ncbi.nlm.nih.gov/34261633/
  250. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34256983/
  251. Thrombocytopenia after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34332437/
  252. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33845870/.
  253. Thrombosis with thrombocytopenia syndrome after COVID-19 immunization:
    https://pubmed.ncbi.nlm.nih.gov/34236343/
  254. Acute myocardial infarction within 24 hours after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34364657/
  255. Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34287612/
  256. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental:
    https://pubmed.ncbi.nlm.nih.gov/34478433/
  257. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea:
    https://pubmed.ncbi.nlm.nih.gov/34402235/
  258. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
  259. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/
  260. A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34137813/
  261. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34191218/
  262. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy:
    https://pubmed.ncbi.nlm.nih.gov/34175640/
  263. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34153802/
  264. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://pubmed.ncbi.nlm.nih.gov/34092488/
  265. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
  266. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34132839/
  267. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34144250/
  268. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/33687691/
  269. Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34011137/
  270. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series:
    https://pubmed.ncbi.nlm.nih.gov/34393988/
  271. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis:
    https://pubmed.ncbi.nlm.nih.gov/34129181/
  272. Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers:
    https://pubmed.ncbi.nlm.nih.gov/34083026/
  273. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/
  274. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage:
    https://pubmed.ncbi.nlm.nih.gov/34235757/
  275. Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34473841/
  276. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
  277. Cerebral venous thrombosis following COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34045111/
  278. Lipschütz ulcers after AstraZeneca COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34366434/
  279. Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34330677/
  280. Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273:
    https://pubmed.ncbi.nlm.nih.gov/34181446/
  281. Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19:
    https://pubmed.ncbi.nlm.nih.gov/34477089/
  282. Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34071883/
  283. Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34033367/
  284. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites:
    https://pubmed.ncbi.nlm.nih.gov/34375510/
  285. Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34107198/
  286. Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature:
    https://pubmed.ncbi.nlm.nih.gov/34355379/
  287. A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA:
    https://pubmed.ncbi.nlm.nih.gov/34452028/
  288. Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
  289. Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
  290. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105247/
  291. Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34405870/
  292. Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34416410/
  293. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34462013/.
  294. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/
  295. Post-vaccinal encephalitis after ChAdOx1 nCov-19:
    https://pubmed.ncbi.nlm.nih.gov/34324214/
  296. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: https://pubmed.ncbi.nlm.nih.gov/34507266/
  297. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34459725/
  298. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19:
    https://pubmed.ncbi.nlm.nih.gov/34463066/
  299. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: https://pubmed.ncbi.nlm.nih.gov/34043800/
  300. Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: https://pubmed.ncbi.nlm.nih.gov/34447646/
  301. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/
  302. Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients:
    https://pubmed.ncbi.nlm.nih.gov/34416319/
  303. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST):
    https://pubmed.ncbi.nlm.nih.gov/34092166/
  304. Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34291477/
  305. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34513435/
  306. Hepatitis C virus reactivation after COVID-19 vaccination: a case report:
    https://pubmed.ncbi.nlm.nih.gov/34512037/
  307. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: https://pubmed.ncbi.nlm.nih.gov/34483273/
  308. Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34513446/
  309. Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34474550/
  310. Reactive arthritis after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34033732/
  311. Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants:
    https://pubmed.ncbi.nlm.nih.gov/33858208/
  312. Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: https://pubmed.ncbi.nlm.nih.gov/34015240/
  313. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19:
    https://pubmed.ncbi.nlm.nih.gov/34482558/
  314. COVID-19 mRNA vaccine causing CNS inflammation: a case series:
    https://pubmed.ncbi.nlm.nih.gov/34480607/
  315. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19:
    https://pubmed.ncbi.nlm.nih.gov/34462647/
  316. Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2:
    https://pubmed.ncbi.nlm.nih.gov/34325334/
  317. Tolosa-Hunt syndrome occurring after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34513398/
  318. Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
  319. Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): https://pubmed.ncbi.nlm.nih.gov/34469919/.
  320. Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: https://pubmed.ncbi.nlm.nih.gov/34516272/
  321. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report:
    https://pubmed.ncbi.nlm.nih.gov/34512961/
  322. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34077949/
  323. Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34171435/
  324. Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report:
    https://pubmed.ncbi.nlm.nih.gov/34447349/
  325. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34514078/
  326. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19:
    https://pubmed.ncbi.nlm.nih.gov/34406660/
  327. IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19:
    https://pubmed.ncbi.nlm.nih.gov/34509658/
  328. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34196469/.
  329. Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases:
    https://pubmed.ncbi.nlm.nih.gov/34350668/
  330. Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34436620/
  331. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
  332. COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems:
    https://pubmed.ncbi.nlm.nih.gov/34509271/
  333. Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34462996/
  334. Immune thrombocytopenia after vaccination during the COVID-19 pandemic:
    https://pubmed.ncbi.nlm.nih.gov/34435486/
  335. COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries:
    https://pubmed.ncbi.nlm.nih.gov/34435142/
  336. Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34429981/
  337. Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: https://pubmed.ncbi.nlm.nih.gov/34427024/
  338. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34510014/
  339. Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34236711/
  340. Vaccine-induced thrombocytopenia with severe headache:
    https://pubmed.ncbi.nlm.nih.gov/34525282/
  341. Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34515024/
  342. Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34435250/
  343. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34363637/
  344. Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2:
    https://www.sciencedirect.com/science/article/pii/S2214250921002018
  345. Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination:
    https://casereports.bmj.com/content/14/5/e242220.abstract
  346. Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34155844/
  347. Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration:
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/
  348. Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine:
    https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.
  349. Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2:
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/
  350. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination:
    https://casereports.bmj.com/content/14/7/e242678
  351. Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination:
    https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic
  352. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794
  353. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria:
    https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in
  354. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany:
    https://pubmed.ncbi.nlm.nih.gov/34288044/
  355. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: https://pubmed.ncbi.nlm.nih.gov/34327553/
  356. Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33878469/
  357. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://pubmed.ncbi.nlm.nih.gov/33857630/
  358. Cerebral venous thrombosis induced by SARS-CoV-2 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34090750/
  359. Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34312301/
  360. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34333995/
  361. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34455073/
  362. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34111775/
  363. Cerebral venous thrombosis after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34045111/
  364. Lethal cerebral venous sinus thrombosis after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33983464/
  365. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: https://pubmed.ncbi.nlm.nih.gov/34116145/
  366. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34286453/
  367. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental:
    https://pubmed.ncbi.nlm.nih.gov/34478433/
  368. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: https://pubmed.ncbi.nlm.nih.gov/34244448/
  369. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S:
    https://pubmed.ncbi.nlm.nih.gov/34226070/
  370. Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: https://pubmed.ncbi.nlm.nih.gov/33845870/
  371. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/.
  372. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series:
    https://pubmed.ncbi.nlm.nih.gov/34393988/
  373. Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome:
    https://pubmed.ncbi.nlm.nih.gov/34407607/
  374. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study:
    https://pubmed.ncbi.nlm.nih.gov/34313952/
  375. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
  376. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
  377. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34274191/
  378. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation:
    https://pubmed.ncbi.nlm.nih.gov/34186376/
  379. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
  380. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis:
    https://pubmed.ncbi.nlm.nih.gov/34129181/
  381. S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021:
    https://pubmed.ncbi.nlm.nih.gov/33929487/
  382. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34341358/
  383. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy:
    https://pubmed.ncbi.nlm.nih.gov/34175640/
  384. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations:
    https://pubmed.ncbi.nlm.nih.gov/34159588/
  385. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
  386. Autoimmunity roots of thrombotic events after vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34508917/
  387. Cerebral venous sinus thrombosis after vaccination: the UK experience:
    https://pubmed.ncbi.nlm.nih.gov/34370974/
  388. Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34373991/
  389. Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34490632/
  390. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33909350/
  391. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: https://pubmed.ncbi.nlm.nih.gov/33981305/.
  392. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/34272622/
  393. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/33877737/
  394. Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34254476/
  395. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland:
    https://pubmed.ncbi.nlm.nih.gov/34108714/
  396. ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand:
    https://pubmed.ncbi.nlm.nih.gov/34483267/
  397. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
  398. Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
  399. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report:
    https://pubmed.ncbi.nlm.nih.gov/34273119/
  400. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19:
    https://pubmed.ncbi.nlm.nih.gov/34463066/
  401. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2:
    https://pubmed.ncbi.nlm.nih.gov/34276917/
  402. Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34237213/
  403. Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT):
    https://pubmed.ncbi.nlm.nih.gov/34268278/
  404. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33990339/
  405. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/
  406. Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery:
    https://pubmed.ncbi.nlm.nih.gov/34314875/
  407. Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34384129/
  408. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: https://pubmed.ncbi.nlm.nih.gov/34382387/
  409. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/
  410. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman:
    https://pubmed.ncbi.nlm.nih.gov/34261297/
  411. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34261296/
  412. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2:
    https://pubmed.ncbi.nlm.nih.gov/34250318/
  413. A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34059191/
  414. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
  415. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/
  416. Vaccine-induced thrombocytopenia with severe headache:
    https://pubmed.ncbi.nlm.nih.gov/34525282/
  417. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database:
    https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
  418. COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis:
    https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.
  419. Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine:
    https://onlinelibrary.wiley.com/doi/10.1111/trf.16672
  420. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: https://t.co/j0IEM8cMXI
  421. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics:
    https://pubmed.ncbi.nlm.nih.gov/34601006/
  422. This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
  423. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report:
    https://www.sciencedirect.com/science/article/pii/S1201971221007797
  424. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database:
    https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
  425. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: https://www.sciencedirect.com/science/article/pii/S0168827821020936
  426. Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: https://www.nature.com/articles/s41421-021-00329-3
  427. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/
  428. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution:
    https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
  429. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome: https://www.science.org/doi/10.1126/sciadv.abl8213
  430. Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.:
    https://pubmed.ncbi.nlm.nih.gov/34626338/
  431. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination:
    https://europepmc.org/article/PPR/PPR308525
  432. VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34731555/
  433. Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations:
    https://pubmed.ncbi.nlm.nih.gov/34159588/
  434. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34461442/
  435. Spectrum of neurological complications after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34719776/
  436. Cerebral venous sinus thrombosis after vaccination: the UK experience:
    https://pubmed.ncbi.nlm.nih.gov/34370974/
  437. Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34373413/
  438. Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19:
    https://pubmed.ncbi.nlm.nih.gov/34598301/
  439. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/
  440. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: https://pubmed.ncbi.nlm.nih.gov/34650896/
  441. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19:
    https://pubmed.ncbi.nlm.nih.gov/34625447/
  442. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: https://pubmed.ncbi.nlm.nih.gov/34696248/
  443. Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34548920/
  444. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE):
    https://pubmed.ncbi.nlm.nih.gov/34672380/
  445. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: https://pubmed.ncbi.nlm.nih.gov/34556531/
  446. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34535076/
  447. Clinical features of vaccine-induced thrombocytopenia and immune thrombosis:
    https://pubmed.ncbi.nlm.nih.gov/34379914/
  448. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: https://pubmed.ncbi.nlm.nih.gov/34545400/
  449. Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34035134/
  450. In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34688190/
  451. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases:
    https://pubmed.ncbi.nlm.nih.gov/34782400/
  452. Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data:
    https://pubmed.ncbi.nlm.nih.gov/34710832/
  453. Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: https://pubmed.ncbi.nlm.nih.gov/34695859/
  454. Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: https://pubmed.ncbi.nlm.nih.gov/34453762/
  455. Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: https://pubmed.ncbi.nlm.nih.gov/34660652/
  456. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: https://pubmed.ncbi.nlm.nih.gov/34644642/
  457. Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: https://pubmed.ncbi.nlm.nih.gov/34694650/
  458. Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34726934/
  459. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: https://pubmed.ncbi.nlm.nih.gov/34835237/
  460. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman:
    https://pubmed.ncbi.nlm.nih.gov/34261297/
  461. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34724036/
  462. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA:
    https://pubmed.ncbi.nlm.nih.gov/34839563/
  463. Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34783932/
  464. COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation:
    https://pubmed.ncbi.nlm.nih.gov/34624910/
  465. Inflammatory myositis after vaccination with ChAdOx1:
    https://pubmed.ncbi.nlm.nih.gov/34585145/
  466. Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT):
    https://pubmed.ncbi.nlm.nih.gov/34580132/
  467. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: https://pubmed.ncbi.nlm.nih.gov/34535492/
  468. COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series:
    https://pubmed.ncbi.nlm.nih.gov/34527501/
  469. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia:
    https://pubmed.ncbi.nlm.nih.gov/34272095/
  470. Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: https://pubmed.ncbi.nlm.nih.gov/34756770/
  471. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine:
    https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622
  472. Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781321/
  473. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines:
    https://pubmed.ncbi.nlm.nih.gov/34062319/
  474. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India:
    https://pubmed.ncbi.nlm.nih.gov/34706921/
  475. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: https://pubmed.ncbi.nlm.nih.gov/34698582/
  476. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19:
    https://pubmed.ncbi.nlm.nih.gov/34751013/
  477. Acute transverse myelitis after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34684047/
  478. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34541935/
  479. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report:
    https://pubmed.ncbi.nlm.nih.gov/34273119/
  480. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: https://pubmed.ncbi.nlm.nih.gov/34327553/
  481. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/33877737/
  482. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34646685/
  483. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34242687/
  484. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34609603/
  485. Case report: Pityriasis rosea-like rash after vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34557507/
  486. Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34641797/.
  487. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222:
    https://pubmed.ncbi.nlm.nih.gov/34812326/
  488. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS):
    https://pubmed.ncbi.nlm.nih.gov/34006408/
  489. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/
  490. Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development:
    https://pubmed.ncbi.nlm.nih.gov/34664303/
  491. Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34649281/
  492. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34420249/
  493. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis:
    https://pubmed.ncbi.nlm.nih.gov/34610990/
  494. Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34590397/
  495. Sudden sensorineural hearing loss after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34670143/
  496. Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: https://pubmed.ncbi.nlm.nih.gov/34819146/
  497. Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34581453/
  498. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: https://pubmed.ncbi.nlm.nih.gov/34741583/
  499. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34631069/
  500. Thrombosis after COVID-19 vaccination: possible link to ACE pathways:
    https://pubmed.ncbi.nlm.nih.gov/34479129/
  501. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/
  502. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): https://pubmed.ncbi.nlm.nih.gov/34546608/
  503. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34546343/
  504. Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34849183/
  505. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34853744/.
  506. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): https://pubmed.ncbi.nlm.nih.gov/34751429/.
  507. Ocular adverse events following COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34559576/
  508. Depression after ChAdOx1-S / nCoV-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34608345/
  509. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34384129/
  510. Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: https://pubmed.ncbi.nlm.nih.gov/34755433/
  511. Major artery thrombosis and vaccination against ChAdOx1 nCov-19:
    https://pubmed.ncbi.nlm.nih.gov/34839830/
  512. Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings:
    https://pubmed.ncbi.nlm.nih.gov/34667486/
  513. Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: https://pubmed.ncbi.nlm.nih.gov/34726187/
  514. Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34781027/
  515. Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: https://pubmed.ncbi.nlm.nih.gov/34595694/
  516. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers:
    https://pubmed.ncbi.nlm.nih.gov/34661934/
  517. Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia:
    https://pubmed.ncbi.nlm.nih.gov/34788138
  518. Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34753210/
  519. Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34653943/
  520. Relapse of immune thrombocytopenia after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34591991/
  521. Thrombosis in pre- and post-vaccination phase of COVID-19;
    https://pubmed.ncbi.nlm.nih.gov/34650382/
  522. A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: https://pubmed.ncbi.nlm.nih.gov/34769454/
  523. COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective:
    https://pubmed.ncbi.nlm.nih.gov/34786893/
  524. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis:
    https://pubmed.ncbi.nlm.nih.gov/34833382/
  525. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen):
    https://pubmed.ncbi.nlm.nih.gov/34670287/
  526. An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34790811/
  527. Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: https://pubmed.ncbi.nlm.nih.gov/34023956/
  528. Thrombosis formation after COVID-19 vaccination immunologic aspects: review article:
    https://pubmed.ncbi.nlm.nih.gov/34629931/
  529. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
  530. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34842783/
  531. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34630307/
  532. Fatal cerebral venous sinus thrombosis after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33983464/
  533. Autoimmune roots of thrombotic events after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34508917/
  534. New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext
  535. Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33962903/
  536. Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34796065/
  537. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: https://pubmed.ncbi.nlm.nih.gov/34579248/
  538. A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis:
    https://pubmed.ncbi.nlm.nih.gov/34843991/
  539. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): https://pubmed.ncbi.nlm.nih.gov/34595867/
  540. A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): https://pubmed.ncbi.nlm.nih.gov/34820240/
  541. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors:
    https://pubmed.ncbi.nlm.nih.gov/33851389/
  542. Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S:
    https://pubmed.ncbi.nlm.nih.gov/33980419/
  543. Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34264151/
  544. Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: https://pubmed.ncbi.nlm.nih.gov/34734086/
  545. Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: https://pubmed.ncbi.nlm.nih.gov/34755555/
  546. Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/
  547. Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34264514/.
  548. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34840204/
  549. Neurological side effects of SARS-CoV-2 vaccines:
    https://pubmed.ncbi.nlm.nih.gov/34750810/
  550. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways:
    https://pubmed.ncbi.nlm.nih.gov/34639132/
  551. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up:
    https://pubmed.ncbi.nlm.nih.gov/34804412/
  552. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report:
    https://pubmed.ncbi.nlm.nih.gov/34571653/
  553. Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: https://pubmed.ncbi.nlm.nih.gov/34835275/.
  554. Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males:
    https://pubmed.ncbi.nlm.nih.gov/34659839/
  555. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series:
    https://pubmed.ncbi.nlm.nih.gov/34668274/
  556. Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34549821/
  557. Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): https://pubmed.ncbi.nlm.nih.gov/34528522/
  558. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19:
    https://pubmed.ncbi.nlm.nih.gov/34568726/
  559. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179
  560. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408
  561. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://www.mdpi.com/2075-4426/11/11/1106
  562. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study:
    https://pubmed.ncbi.nlm.nih.gov/34402230/
  563. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
  564. Myocarditis Following mRNA COVID-19 Vaccine: https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx
  565. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel:
    https://pubmed.ncbi.nlm.nih.gov/34614328/
  566. Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination:
    https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext
  567. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
  568. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: https://pubmed.ncbi.nlm.nih.gov/34246586/
  569. Hypersensitivity Myocarditis and COVID-19 Vaccines:
    https://pubmed.ncbi.nlm.nih.gov/34856634/
  570. Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?:
    https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext
  571. Acute myocardial infarction and myocarditis after COVID-19 vaccination:
    https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/
  572. Myocarditis after Covid-19 vaccination in a large healthcare organization:
    https://www.nejm.org/doi/10.1056/NEJMoa2110737
  573. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
  574. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults:
    https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
  575. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. https://pubmed.ncbi.nlm.nih.gov/34756746/
  576. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center:
    https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/
  577. Myocarditis after COVID-19 mRNA vaccines:
    https://pubmed.ncbi.nlm.nih.gov/34546329/
  578. Patients with acute myocarditis after COVID-19 mRNA vaccination:.
    https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602
  579. Myocarditis after COVID-19 vaccination: a case series:
    https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub
  580. Myocarditis associated with COVID-19 vaccination in adolescents:
    https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357
  581. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34704459/
  582. Myocarditis after COVID-19 vaccination: magnetic resonance imaging study:
    https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6421640
  583. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/
  584. Myocarditis after COVID-19 vaccination:
    https://www.sciencedirect.com/science/article/pii/S2352906721001603
  585. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy:
    https://pubmed.ncbi.nlm.nih.gov/34712717/
  586. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:
    https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration-bnt162b2-S188558572100133X
  587. Myocarditis associated with COVID-19 mRNA vaccination:
    https://pubs.rsna.org/doi/10.1148/radiol.2021211430
  588. Acute myocarditis after COVID-19 vaccination: a case report:
    https://www.sciencedirect.com/science/article/pii/S0248866321007098
  589. Acute myopericarditis after COVID-19 vaccination in adolescents:
    https://pubmed.ncbi.nlm.nih.gov/34589238/
  590. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination:
    https://academic.oup.com/jpids/article/10/10/962/6329543
  591. Acute myocarditis associated with anti-COVID-19 vaccination:
    https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196
  592. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. https://pubmed.ncbi.nlm.nih.gov/34428917/
  593. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. https://pubmed.ncbi.nlm.nih.gov/34088762/.
  594. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines: https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/6442104
  595. COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis:
    https://www.mdpi.com/2036-7503/13/3/61
  596. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA:
    https://pubmed.ncbi.nlm.nih.gov/34402228/
  597. Myocarditis temporally associated with COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34133885/
  598. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database:
    https://pubmed.ncbi.nlm.nih.gov/34219532/
  599. Acute myocarditis associated with COVID-19 vaccination: report of a case:
    https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/
  600. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: https://pubmed.ncbi.nlm.nih.gov/34840235/.
  601. Myocarditis in the setting of a recent COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34712497/
  602. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext
  603. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19:
    https://pubmed.ncbi.nlm.nih.gov/34568726/
  604. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179
  605. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408
  606. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://www.mdpi.com/2075-4426/11/11/1106
  607. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study:
    https://pubmed.ncbi.nlm.nih.gov/34402230/
  608. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
  609. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34615534/
  610. Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352418/
  611. Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340
  612. COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count:
    https://pubmed.ncbi.nlm.nih.gov/34632750/
  613. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia:
    https://haematologica.org/article/view/haematol.2021.279075
  614. COVID-19 vaccine-induced thrombosis: https://pubmed.ncbi.nlm.nih.gov/34802488/
  615. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis:
    https://pubmed.ncbi.nlm.nih.gov/34887867/
  616. Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34863404/
  617. Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience:
    https://www.sciencedirect.com/science/article/pii/S235255682100093X
  618. Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34876440/
  619. Deep venous thrombosis more than two weeks after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33928773/
  620. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome:
    https://pubmed.ncbi.nlm.nih.gov/34880826/
  621. Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34587242/
  622. Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: https://pubmed.ncbi.nlm.nih.gov/34868465/
  623. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT):
    https://pubmed.ncbi.nlm.nih.gov/34097311/
  624. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors:
    https://pubmed.ncbi.nlm.nih.gov/34820232/
  625. Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258
  626. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: https://pubmed.ncbi.nlm.nih.gov/34579636/
  627. Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: https://pubmed.ncbi.nlm.nih.gov/34614491/
  628. Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273:
    https://pubmed.ncbi.nlm.nih.gov/34790684/
  629. Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33624509/
  630. Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): https://pubmed.ncbi.nlm.nih.gov/34612003/
  631. Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism:
    https://pubmed.ncbi.nlm.nih.gov/34096082/
  632. Myocarditis associated with COVID-19 vaccination in three adolescent boys:
    https://pubmed.ncbi.nlm.nih.gov/34851078/
  633. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series:
    https://pubmed.ncbi.nlm.nih.gov/34496880/
  634. Perimyocarditis after vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34866957/
  635. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://pubmed.ncbi.nlm.nih.gov/34849657/.
  636. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings:
    https://pubmed.ncbi.nlm.nih.gov/34664804/
  637. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: https://pubmed.ncbi.nlm.nih.gov/34605853/
  638. Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male:
    https://pubmed.ncbi.nlm.nih.gov/34166671/
  639. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34744118/
  640. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male:
    https://pubmed.ncbi.nlm.nih.gov/34334935/
  641. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34746968/
  642. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”:
    https://pubmed.ncbi.nlm.nih.gov/34333695/
  643. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34180390/
  644. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: https://pubmed.ncbi.nlm.nih.gov/34185045/
  645. Myocarditis after BNT162b2 vaccination in a healthy male:
    https://pubmed.ncbi.nlm.nih.gov/34229940/
  646. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
  647. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34308326/
  648. Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: https://pubmed.ncbi.nlm.nih.gov/34866106/
  649. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
  650. Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273:
    https://pubmed.ncbi.nlm.nih.gov/34848416/
  651. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: https://pubmed.ncbi.nlm.nih.gov/34636504/
  652. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34367386/
  653. Acute myocarditis in a young adult two days after vaccination with Pfizer:
    https://pubmed.ncbi.nlm.nih.gov/34709227/
  654. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: https://pubmed.ncbi.nlm.nih.gov/34778411/
  655. Acute myocarditis after 2019 coronavirus disease vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34734821/
  656. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34246585/
  657. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34228985/
  658. Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34852213/
  659. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease:
    https://pubmed.ncbi.nlm.nih.gov/34866122/
  660. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: https://pubmed.ncbi.nlm.nih.gov/34601566/
  661. Myocarditis following COVID-19 vaccination: MRI study:
    https://pubmed.ncbi.nlm.nih.gov/34739045/
  662. Acute myocarditis after COVID-19 vaccination: case report:
    https://pubmed.ncbi.nlm.nih.gov/34740463/
  663. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
  664. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https://pubmed.ncbi.nlm.nih.gov/34865500/
  665. Myocarditis following vaccination with Covid-19 in a large healthcare organization:
    https://pubmed.ncbi.nlm.nih.gov/34614329/
  666. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: https://pubmed.ncbi.nlm.nih.gov/34560365/
  667. COVID-19, Guillain-Barré and vaccineA dangerous mix:
    https://pubmed.ncbi.nlm.nih.gov/34108736/
  668. Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: https://pubmed.ncbi.nlm.nih.gov/34796417/
  669. Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine:
    https://link.springer.com/article/10.1007%2Fs10072-021-05523-5
  670. COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy:
    https://onlinelibrary.wiley.com/doi/10.1002/ana.26258
  671. Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021:
    https://jamanetwork.com/journals/jama/fullarticle/2785009
  672. A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34567447/
  673. Guillain-Barré syndrome associated with COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34648420/
  674. Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708
  675. Guillain-Barre syndrome after COVID-19 vaccination in an adolescent:
    https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext
  676. Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34114256/
  677. Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report:
    https://pubmed.ncbi.nlm.nih.gov/34767184/
  678. Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients:
    https://pubmed.ncbi.nlm.nih.gov/34644738/
  679. Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: https://pubmed.ncbi.nlm.nih.gov/34649856/
  680. A rare case of Guillain-Barré syndrome after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34671572/
  681. Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33758714/
  682. COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: https://pubmed.ncbi.nlm.nih.gov/34484780/
  683. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report:
    https://pubmed.ncbi.nlm.nih.gov/34779385/
  684. Miller Fisher syndrome after Pfizer COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34817727/
  685. Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34789193/
  686. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261746/
  687. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://pubmed.ncbi.nlm.nih.gov/34217513/.
  688. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer):
    https://pubmed.ncbi.nlm.nih.gov/34871447/
  689. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: https://pubmed.ncbi.nlm.nih.gov/34579259/
  690. A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN:
    https://pubmed.ncbi.nlm.nih.gov/34370408/
  691. A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S:
    https://pubmed.ncbi.nlm.nih.gov/34703690/
  692. Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome:
    https://pubmed.ncbi.nlm.nih.gov/34810163/
  693. Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: https://onlinelibrary.wiley.com/doi/10.1002/ana.26218
  694. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34482455/
  695. Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34114269/
  696. Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: https://pubmed.ncbi.nlm.nih.gov/34722067/
  697. Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: https://pubmed.ncbi.nlm.nih.gov/33968610/
  698. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: https://pubmed.ncbi.nlm.nih.gov/34525410/
  699. Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34808658/
  700. Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination:
    https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext
  701. Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence:
    https://pubmed.ncbi.nlm.nih.gov/34522557/
  702. Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report:
    https://pubmed.ncbi.nlm.nih.gov/34763263/
  703. Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: https://pubmed.ncbi.nlm.nih.gov/34621891/
  704. Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34697502/
  705. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: https://pubmed.ncbi.nlm.nih.gov/33858693/
  706. Acute transverse myelitis following inactivated COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34370410/
  707. Acute transverse myelitis after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34579245/
  708. A case of longitudinally extensive transverse myelitis following Covid-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34182207/
  709. Post COVID-19 transverse myelitis; a case report with review of the literature:
    https://pubmed.ncbi.nlm.nih.gov/34457267/
  710. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/
  711. Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273:
    https://pubmed.ncbi.nlm.nih.gov/34660149/
  712. Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34131771/
  713. A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States:
    https://pubmed.ncbi.nlm.nih.gov/34635376/
  714. Acute pericarditis and cardiac tamponade after vaccination with Covid-19:
    https://pubmed.ncbi.nlm.nih.gov/34749492/
  715. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34849667/
  716. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34319393/
  717. Acute myopericarditis after COVID-19 vaccine in adolescents:
    https://pubmed.ncbi.nlm.nih.gov/34589238/
  718. Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34149145/
  719. Case report: symptomatic pericarditis post COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34693198/
  720. An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient:
    https://pubmed.ncbi.nlm.nih.gov/34797392/
  721. Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19):
    https://pubmed.ncbi.nlm.nih.gov/34862234/
  722. Myocarditis after SARS-CoV-2 mRNA vaccination, a case series:
    https://pubmed.ncbi.nlm.nih.gov/34396358/
  723. Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34848426/
  724. Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2:
    https://pubmed.ncbi.nlm.nih.gov/33946748/
  725. Post-mortem investigation of deaths after vaccination with COVID-19 vaccines:
    https://pubmed.ncbi.nlm.nih.gov/34591186/
  726. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352309/
  727. Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: https://pubmed.ncbi.nlm.nih.gov/34804803/
  728. Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: https://pubmed.ncbi.nlm.nih.gov/34077572/
  729. Retinal hemorrhage after SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34884407/
  730. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34859017/
  731. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report:
    https://pubmed.ncbi.nlm.nih.gov/34783899/
  732. Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34549178/
  733. Brain death in a vaccinated patient with COVID-19 infection:
    https://pubmed.ncbi.nlm.nih.gov/34656887/
  734. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34236717/
  735. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34729467/
  736. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33932458/
  737. Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: https://pubmed.ncbi.nlm.nih.gov/34092400/742
  738. Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34754937/
  739. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/33771584/
  740. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34846583/
  741. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
  742. Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study:
    https://pubmed.ncbi.nlm.nih.gov/34411532/
  743. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval:
    https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1
  744. Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria:
    https://pubmed.ncbi.nlm.nih.gov/33851711/
  745. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: https://pubmed.ncbi.nlm.nih.gov/34675550/
  746. Anaphylaxis after Modern COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34734159/
  747. Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34698847/
  748. Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34020815/
  749. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020:
    https://pubmed.ncbi.nlm.nih.gov/33641264/
  750. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021:
    https://pubmed.ncbi.nlm.nih.gov/33641268/
  751. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: https://pubmed.ncbi.nlm.nih.gov/33834172/
  752. Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34579211/
  753. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result:
    https://pubmed.ncbi.nlm.nih.gov/34343674/
  754. Acute myocardial infarction and myocarditis after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34586408/
  755. Takotsubo syndrome after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34539938/
  756. Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: https://pubmed.ncbi.nlm.nih.gov/34731486/
  757. Premature myocardial infarction or side effect of COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/33824804/
  758. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older:
    https://pubmed.ncbi.nlm.nih.gov/34807248/
  759. Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34148772/
  760. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: https://pubmed.ncbi.nlm.nih.gov/34702550/
  761. Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty®): https://pubmed.ncbi.nlm.nih.gov/33895650/
  762. Deaths associated with recently launched SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34425384/
  763. A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect:
    https://pubmed.ncbi.nlm.nih.gov/34703815/
  764. COVID-19 vaccine-induced urticarial vasculitis:
    https://pubmed.ncbi.nlm.nih.gov/34369046/
  765. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34280507/
  766. New-onset leukocytoclastic vasculitis after COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34241833/
  767. Cutaneous small vessel vasculitis after COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34529877/.
  768. Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/33928638/
  769. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34836739/
  770. Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?: https://pubmed.ncbi.nlm.nih.gov/34495381/
  771. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34327795
  772. Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34660867/
  773. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34659268/
  774. Reactivation of IgA vasculitis after vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34848431/
  775. Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34310759/
  776. Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: https://pubmed.ncbi.nlm.nih.gov/34720009/
  777. A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34518812/
  778. Cutaneous vasculitis following COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34611627/
  779. Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis:
    https://pubmed.ncbi.nlm.nih.gov/34705320/
  780. IgA vasculitis following COVID-19 vaccination in an adult:
    https://pubmed.ncbi.nlm.nih.gov/34779011/
  781. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34451967/
  782. Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis:
    https://pubmed.ncbi.nlm.nih.gov/33928459/
  783. Reactivation of IgA vasculitis after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34250509/
  784. Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34292611/
  785. First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: https://pubmed.ncbi.nlm.nih.gov/34530771/
  786. Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: https://pubmed.ncbi.nlm.nih.gov/34245294/.
  787. Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34599716/
  788. Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: https://pubmed.ncbi.nlm.nih.gov/34115904/
  789. Henoch-Schönlein purpura occurring after vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34247902/
  790. Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34696186/.
  791. Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34237323/
  792. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34851795/
  793. A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34849386/
  794. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2:
    https://pubmed.ncbi.nlm.nih.gov/34310763/
  795. Relapse of microscopic polyangiitis after COVID-19 vaccination: case report:
    https://pubmed.ncbi.nlm.nih.gov/34251683/
  796. Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34557622/
  797. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/34510694/
  798. Leukocytoclastic vasculitis after coronavirus disease vaccination 2019:
    https://pubmed.ncbi.nlm.nih.gov/34713472/803
  799. Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2:
    https://pubmed.ncbi.nlm.nih.gov/34819272/
  800. Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34337124/
  801. Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: https://pubmed.ncbi.nlm.nih.gov/34535924/
  802. Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report:
    https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/
  803. COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: https://pubmed.ncbi.nlm.nih.gov/33591026/
  804. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: https://pubmed.ncbi.nlm.nih.gov/33625300/
  805. Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: https://pubmed.ncbi.nlm.nih.gov/33774684/
  806. Lymphadenopathy after COVID-19 vaccination: review of imaging findings:
    https://pubmed.ncbi.nlm.nih.gov/33985872/
  807. Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34735411/
  808. Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine:
    https://pubmed.ncbi.nlm.nih.gov/34115709/
  809. COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: https://pubmed.ncbi.nlm.nih.gov/34257025/
  810. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: https://pubmed.ncbi.nlm.nih.gov/34836672/
  811. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study:
    https://pubmed.ncbi.nlm.nih.gov/34280870/
  812. COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: https://pubmed.ncbi.nlm.nih.gov/34432391/
  813. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care:
    https://pubmed.ncbi.nlm.nih.gov/34731748/
  814. Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: https://pubmed.ncbi.nlm.nih.gov/34906409/
  815. Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
  816. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
  817. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
  818. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
  819. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
  820. A case of cervical lymphadenopathy following COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34141500/
  821. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
  822. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
  823. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
  824. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up:
    https://pubmed.ncbi.nlm.nih.gov/34298342/
  825. A systematic review of cases of CNS demyelination following COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34839149/
  826. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic:
    https://pubmed.ncbi.nlm.nih.gov/33685772/
  827. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
  828. Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/
  829. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34292295/
  830. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/
  831. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services:
    https://pubmed.ncbi.nlm.nih.gov/34526175/
  832. Lymphadenopathy associated with the COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/33786231/
  833. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33625301/
  834. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34332438/
  835. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/
  836. Massive cervical lymphadenopathy following vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34601889/
  837. ANCA glomerulonephritis following Modern COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34081948/
  838. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.
  839. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
  840. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
  841. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
  842. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
  843. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
  844. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34187985/
  845. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
  846. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
  847. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
  848. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
  849. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
  850. A case of cervical lymphadenopathy following COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34141500/
  851. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
  852. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
  853. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
  854. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up:
    https://pubmed.ncbi.nlm.nih.gov/34298342/
  855. A systematic review of cases of CNS demyelination following COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34839149/
  856. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic:
    https://pubmed.ncbi.nlm.nih.gov/33685772/
  857. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
  858. Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/.
  859. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34292295/
  860. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/
  861. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services:
    https://pubmed.ncbi.nlm.nih.gov/34526175/
  862. Lymphadenopathy associated with the COVID-19 vaccine:
    https://pubmed.ncbi.nlm.nih.gov/33786231/
  863. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/33625301/
  864. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34332438/
  865. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/
  866. Massive cervical lymphadenopathy following vaccination with COVID-19:
    https://pubmed.ncbi.nlm.nih.gov/34601889/
  867. ANCA glomerulonephritis following Modern COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34081948/
  868. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.
  869. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
  870. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
  871. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/
  872. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
  873. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/
  874. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination:
    https://pubmed.ncbi.nlm.nih.gov/34187985/
  875. Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018: https://www.ncbi.nlm.nih.gov/pubmed/34416319
  876. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087:
    https://www.ncbi.nlm.nih.gov/pubmed/34092429
  877. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/ j.radcr.2021.05.033: https://www.ncbi.nlm.nih.gov/pubmed/34025885
  878. Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252: https://www.ncbi.nlm.nih.gov/pubmed/34586408
  879. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017:
    https://www.ncbi.nlm.nih.gov/pubmed/34756746
  880. Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475:
    https://www.ncbi.nlm.nih.gov/pubmed/34432976
  881. Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556: https://www.ncbi.nlm.nih.gov/pubmed/34754400
  882. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135:
    https://www.ncbi.nlm.nih.gov/pubmed/34281357
  883. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390 /vaccines9111353: https://www.ncbi.nlm.nih.gov/pubmed/34835284
  884. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232:
    https://www.ncbi.nlm.nih.gov/pubmed/34366403
  885. Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061:
    https://www.ncbi.nlm.nih.gov/pubmed/34564344
  886. Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141: https://www.ncbi.nlm.nih.gov/pubmed/34617315
  887. Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w:
    https://www.ncbi.nlm.nih.gov/pubmed/34333695
  888. Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163:
    https://www.ncbi.nlm.nih.gov/pubmed/34833382
  889. Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853:
    https://www.ncbi.nlm.nih.gov/pubmed/34704459
  890. Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286: https://www.ncbi.nlm.nih.gov/pubmed/34664804
  891. Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499:
    https://www.ncbi.nlm.nih.gov/pubmed/34860360
  892. Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989:
    https://www.ncbi.nlm.nih.gov/pubmed/34849657
  893. Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026: https://www.ncbi.nlm.nih.gov/pubmed/34933012
  894. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026:
    https://www.ncbi.nlm.nih.gov/pubmed/34547487
  895. Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/ j.jpeds.2021.07.044: https://www.ncbi.nlm.nih.gov/pubmed/34339728
  896. Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607:
    https://www.ncbi.nlm.nih.gov/pubmed/34356586
  897. Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230:
    https://www.ncbi.nlm.nih.gov/pubmed/34219532
  898. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003: https://www.ncbi.nlm.nih.gov/pubmed/34246585
  899. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977:
    https://www.ncbi.nlm.nih.gov/pubmed/34492161
  900. Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607: https://www.ncbi.nlm.nih.gov/pubmed/34844930
  901. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6:
    https://www.ncbi.nlm.nih.gov/pubmed/34487236
  902. El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/ NEJMoa2113017: https://www.ncbi.nlm.nih.gov/pubmed/34551225
  903. Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746:
    https://www.ncbi.nlm.nih.gov/pubmed/34709227
  904. Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318: https://www.ncbi.nlm.nih.gov/pubmed/34921468
  905. Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y: https://www.ncbi.nlm.nih.gov/pubmed/34824230
  906. Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x:
    https://www.ncbi.nlm.nih.gov/pubmed/34170372
  907. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ ehjqcco/qcab090: https://www.ncbi.nlm.nih.gov/pubmed/34849667
  908. Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021: https://www.ncbi.nlm.nih.gov/pubmed/34646267
  909. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/ annrheumdis-2021-220647 https://www.ncbi.nlm.nih.gov/pubmed/34127481
  910. Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004:
    https://www.ncbi.nlm.nih.gov/pubmed/34538306
  911. Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2: https://www.ncbi.nlm.nih.gov/pubmed/34237049
  912. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019:
    https://www.ncbi.nlm.nih.gov/pubmed/33406694
  913. Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890: https://www.ncbi.nlm.nih.gov/pubmed/34660088
  914. Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090: https://www.ncbi.nlm.nih.gov/pubmed/34916217
  915. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006:
    https://www.ncbi.nlm.nih.gov/pubmed/34153517
  916. Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087: https://www.ncbi.nlm.nih.gov/pubmed/34668687
  917. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3: https://www.ncbi.nlm.nih.gov/pubmed/34348657
  918. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1: https://www.ncbi.nlm.nih.gov/pubmed/34351881
  919. Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047:
    https://www.ncbi.nlm.nih.gov/pubmed/33854395
  920. Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931: https://www.ncbi.nlm.nih.gov/pubmed/34446426
  921. Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210:
    https://www.ncbi.nlm.nih.gov/pubmed/34808708
  922. Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9:
    https://www.ncbi.nlm.nih.gov/pubmed/34347278
  923. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from:
    https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/3454412
  924. Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231: https://www.ncbi.nlm.nih.gov/pubmed/34463755
  925. Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326:
    https://www.ncbi.nlm.nih.gov/pubmed/34931681
  926. Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766:
    https://www.ncbi.nlm.nih.gov/pubmed/34342500
  927. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18:
    https://www.ncbi.nlm.nih.gov/pubmed/34805376
  928. Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177: https://www.ncbi.nlm.nih.gov/pubmed/34834983
  929. Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427:
    https://www.ncbi.nlm.nih.gov/pubmed/34389692
  930. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061: https://www.ncbi.nlm.nih.gov/pubmed/34270752
  931. Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818:
    https://www.ncbi.nlm.nih.gov/pubmed/34744118
  932. Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872:
    https://www.ncbi.nlm.nih.gov/pubmed/34568540
  933. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590: https://www.ncbi.nlm.nih.gov/pubmed/34447639
  934. Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828:
    https://www.ncbi.nlm.nih.gov/pubmed/34185046
  935. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229: https://www.ncbi.nlm.nih.gov/pubmed/34402228
  936. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042:
    https://www.ncbi.nlm.nih.gov/pubmed/34396358
  937. Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072:
    https://www.ncbi.nlm.nih.gov/pubmed/34477808
  938. Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7:
    https://www.ncbi.nlm.nih.gov/pubmed/33898162
  939. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4: https://www.ncbi.nlm.nih.gov/pubmed/33643776
  940. Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025:
    https://www.ncbi.nlm.nih.gov/pubmed/34952008
  941. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003: https://www.ncbi.nlm.nih.gov/pubmed/34642628
  942. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010:
    https://www.ncbi.nlm.nih.gov/pubmed/34540594
  943. Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y:
    https://www.ncbi.nlm.nih.gov/pubmed/34378087
  944. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7: https://www.ncbi.nlm.nih.gov/pubmed/34127854
  945. Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120:
    https://www.ncbi.nlm.nih.gov/pubmed/34393110
  946. Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232: https://www.ncbi.nlm.nih.gov/pubmed/34463770
  947. Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132:
    https://www.ncbi.nlm.nih.gov/pubmed/33606296
  948. Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004:
    https://www.ncbi.nlm.nih.gov/pubmed/34535317
  949. Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9:
    https://www.ncbi.nlm.nih.gov/pubmed/33888900
  950. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11). doi:10.3390/jpm11111106:
    https://www.ncbi.nlm.nih.gov/pubmed/34834458
  951. Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996:
    https://www.ncbi.nlm.nih.gov/pubmed/34778411
  952. Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057: https://www.ncbi.nlm.nih.gov/pubmed/34332972
  953. Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001: https://www.ncbi.nlm.nih.gov/pubmed/34375696
  954. Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. doi:10.1093/cid/ ciab954: https://www.ncbi.nlm.nih.gov/pubmed/34791081
  955. Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age. Case Rep Pediatr, 2021, 6901131. doi:10.1155/2021/6901131: https://www.ncbi.nlm.nih.gov/pubmed/34676123
  956. Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer, 68(11), e29295. doi:10.1002/ pbc.29295: https://www.ncbi.nlm.nih.gov/pubmed/34398511
  957. Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study. Public Health, 190, 4-6. doi:10.1016/j.puhe.2020.11.005:
    https://www.ncbi.nlm.nih.gov/pubmed/33316478
  958. McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322: https://www.ncbi.nlm.nih.gov/pubmed/34133825
  959. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730:
    https://www.ncbi.nlm.nih.gov/pubmed/34614328
  960. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323. doi:10.1016/ j.jpeds.2021.06.035: https://www.ncbi.nlm.nih.gov/pubmed/34166671
  961. Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun, 12(1), 6379. doi:10.1038/s41467-021-26672-3:
    https://www.ncbi.nlm.nih.gov/pubmed/34737312
  962. Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-20:
    https://www.ncbi.nlm.nih.gov/pubmed/33526560
  963. Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-06949-0: https://www.ncbi.nlm.nih.gov/pubmed/34930152
  964. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi:10.1001 /jamacardio.2021.2833: https://www.ncbi.nlm.nih.gov/pubmed/34185045
  965. Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21:
    https://www.ncbi.nlm.nih.gov/pubmed/34840235
  966. Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006:
    https://www.ncbi.nlm.nih.gov/pubmed/34876937
  967. Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765. doi:10.1016/j.clim.2021.108765:
    https://www.ncbi.nlm.nih.gov/pubmed/34089859
  968. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389: https://www.ncbi.nlm.nih.gov/pubmed/34889875
  969. Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-4:
    https://www.ncbi.nlm.nih.gov/pubmed/34320609
  970. Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232. doi:10.3346/jkms.2021.36.e232:
    https://www.ncbi.nlm.nih.gov/pubmed/34402230
  971. Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young, 1-4. doi:10.1017/S1047951121002547:
    https://www.ncbi.nlm.nih.gov/pubmed/34180390
  972. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-4: https://www.ncbi.nlm.nih.gov/pubmed/34496880
  973. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038/s41591-021-01630-0: https://www.ncbi.nlm.nih.gov/pubmed/34907393
  974. Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082: https://www.ncbi.nlm.nih.gov/pubmed/34367386
  975. Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. doi:10.1093/cid/ciab926:
    https://www.ncbi.nlm.nih.gov/pubmed/34734240
  976. Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-9:
    https://www.ncbi.nlm.nih.gov/pubmed/34738774
  977. Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42. doi:10.1002/ajh.26385:
    https://www.ncbi.nlm.nih.gov/pubmed/34695229
  978. Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. Eur J Cancer, 154, 30-34. doi:10.1016/j.ejca. 2021.06.002: https://www.ncbi.nlm.nih.gov/pubmed/34233234
  979. Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6), e210252. doi:10.1148/ryct.210252:
    https://www.ncbi.nlm.nih.gov/pubmed/34934954
  980. Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/ j.jpeds.2021.06.083: https://www.ncbi.nlm.nih.gov/pubmed/34228985
  981. Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-9: https://www.ncbi.nlm.nih.gov/pubmed/34591186
  982. Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-5:
    https://www.ncbi.nlm.nih.gov/pubmed/34241676
  983. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24). doi:10.3390/jcm10245876:
    https://www.ncbi.nlm.nih.gov/pubmed/34945172
  984. Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12, 714170. doi:10.3389/fimmu.2021.714170:
    https://www.ncbi.nlm.nih.gov/pubmed/34707602
  985. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2: https://www.ncbi.nlm.nih.gov/pubmed/33956784
  986. Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383. doi:10.7759/ cureus.16383: https://www.ncbi.nlm.nih.gov/pubmed/34408937
  987. Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jeab230:
    https://www.ncbi.nlm.nih.gov/pubmed/34739045
  988. Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511:
    https://www.ncbi.nlm.nih.gov/pubmed/34605853
  989. Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101/ 2021.07.23.21260998: https://www.ncbi.nlm.nih.gov/pubmed/34341797
  990. Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. doi:10.1038/s41591-021-01578-1:
    https://www.ncbi.nlm.nih.gov/pubmed/34764489
  991. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363. doi:10.1097/INF.0000000000003235: https://www.ncbi.nlm.nih.gov/pubmed/34077949
  992. Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant.doi:10.1016/j.healun.2021.11.001:
    https://www.ncbi.nlm.nih.gov/pubmed/34911654
  993. Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-E411. doi:10.1148/radiol.2021211430:
    https://www.ncbi.nlm.nih.gov/pubmed/34282971
  994. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review. Cardiovasc Revasc Med. doi:10.1016/j.carrev.2021.08.012:
    https://www.ncbi.nlm.nih.gov/pubmed/34420869
  995. Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093/ehjcr/ytab319:
    https://www.ncbi.nlm.nih.gov/pubmed/34514306
  996. Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J. doi:10.1253/circj.CJ-21-0935: https://www.ncbi.nlm.nih.gov/pubmed/34955479
  997. Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi:10.15585/ mmwr.mm7002e1: https://www.ncbi.nlm.nih.gov/pubmed/33444297
  998. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329. doi:10.1056/NEJMoa2107058:
    https://www.ncbi.nlm.nih.gov/pubmed/34192428
  999. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177/11795468211056634:
    https://www.ncbi.nlm.nih.gov/pubmed/34866957
  1000. Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults. Circulation. doi:10.1161/ CIRCULATIONAHA.121.056583: https://www.ncbi.nlm.nih.gov/pubmed/34865500
  1001. Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926. doi:10.1016/j.cpcardiol.2021.100926:
    https://www.ncbi.nlm.nih.gov/pubmed/34311983
  1002. Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002:
    https://www.ncbi.nlm.nih.gov/pubmed/34904134
  1003. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. Cureus, 13(6), e15576. doi:10.7759/cureus.15576:
    https://www.ncbi.nlm.nih.gov/pubmed/34277198
  1004. Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584. doi:10.1097/ PEC.0000000000002557: https://www.ncbi.nlm.nih.gov/pubmed/34731877
  1005. Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524. doi:10.1001/jamanetworkopen.2021.25524:
    https://www.ncbi.nlm.nih.gov/pubmed/34533570
  1006. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016/ j.ajem.2021.06.051: https://www.ncbi.nlm.nih.gov/pubmed/34229940
  1007. Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System. Front Public Health, 9, 695807. doi:10.3389/fpubh.2021.695807: https://www.ncbi.nlm.nih.gov/pubmed/34336774
  1008. Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332. doi:10.1016/j.vaccine.2021.04.054: https://www.ncbi.nlm.nih.gov/pubmed/34006408
  1009. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737:
    https://www.ncbi.nlm.nih.gov/pubmed/34614329
  1010. Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136/archdischild-2020-320338:
    https://www.ncbi.nlm.nih.gov/pubmed/33262177

Последно от ЛЮБОПИТНО